{
    "id": "correct_foundationPlace_00080_1",
    "rank": 46,
    "data": {
        "url": "https://fnih.org/who-we-are/board-of-directors-governance/",
        "read_more_link": "",
        "language": "en",
        "title": "Board of Directors + Governance",
        "top_image": "https://fnih.org/wp-content/uploads/2023/06/FNIHH.png",
        "meta_img": "https://fnih.org/wp-content/uploads/2023/06/FNIHH.png",
        "images": [
            "https://fnih.org/wp-content/uploads/2023/03/ftr-logo.svg",
            "https://fnih.org/wp-content/uploads/2023/04/P2_Mobile_BoardofDirectorsGovernance-Getty-607477465.jpg",
            "https://fnih.org/wp-content/uploads/2023/04/Steve-Paul-180x180.jpg",
            "https://fnih.org/wp-content/uploads/2023/04/director2.png",
            "https://fnih.org/wp-content/uploads/2023/04/director3.png",
            "https://fnih.org/wp-content/uploads/2023/04/director13-1.png",
            "https://fnih.org/wp-content/uploads/2023/05/Mrs.-Blairs-Headshot-180x154.jpg",
            "https://fnih.org/wp-content/uploads/2023/05/Jay-Bradner-122x180.png",
            "https://fnih.org/wp-content/uploads/2024/05/James-Down-e1716566238511-151x180.jpg",
            "https://fnih.org/wp-content/uploads/2024/01/Nina-Kjellson-Headshot-Q1.23-1-176x180.jpg",
            "https://fnih.org/wp-content/uploads/2023/04/director11-1.png",
            "https://fnih.org/wp-content/uploads/2023/04/director10.png",
            "https://fnih.org/wp-content/uploads/2023/04/director12-1.png",
            "https://fnih.org/wp-content/uploads/2023/04/director14-1.png",
            "https://fnih.org/wp-content/uploads/2023/05/DCMBhdsMar230094-120x180.jpg",
            "https://fnih.org/wp-content/uploads/2023/11/Reinhardt-180x180.jpg",
            "https://fnih.org/wp-content/uploads/2023/04/director18-1.png",
            "https://fnih.org/wp-content/uploads/2023/04/director19-1.png",
            "https://fnih.org/wp-content/uploads/2023/05/EllenSigal_1x1-Crop-180x180.png",
            "https://fnih.org/wp-content/uploads/2024/05/Perry_Steiner-003-144x180.png",
            "https://fnih.org/wp-content/uploads/2023/05/Russell-W-180x180.png",
            "https://fnih.org/wp-content/uploads/2023/04/director22-1.png",
            "https://fnih.org/wp-content/uploads/2023/05/Jim-Weiss-122x180.png",
            "https://fnih.org/wp-content/uploads/2023/04/director23-2.png",
            "https://fnih.org/wp-content/uploads/2023/03/mob-logo.svg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": "2023-03-22T04:39:32+00:00",
        "summary": "",
        "meta_description": "",
        "meta_lang": "en",
        "meta_favicon": "https://fnih.org/wp-content/uploads/2023/03/favicon.svg",
        "meta_site_name": "FNIH",
        "canonical_link": "https://fnih.org/who-we-are/board-of-directors-governance/",
        "text": "Dr. Steve Paul is the Chief Scientific Officer, President of Research and Development, and a member of the board of directors at Karuna Therapeutics. He most recently served as Chairman of the Board, President, and Chief Executive Officer from 2018 – 2022. He is an expert in central nervous system (CNS) drug discovery and development. Dr. Paul spent 17 years at Eli Lilly and Company (NYSE: LLY), during which time he held several key leadership roles, including Executive Vice President for Science and Technology and President of the Lilly Research Laboratories. At Lilly he was responsible for the company’s overall research and development efforts and helped to oversee the development of CNS drugs such as Zyprexa® and Cymbalta® as well as the development of xanomeline where its antipsychotic and procognitive properties were initially demonstrated. Prior to Lilly, Dr. Paul spent 18 years at the National Institute of Health (NIH) and served as the Scientific Director of the National Institute of Mental Health (NIMH). Dr. Paul is a co-founder and board member of Sage Therapeutics (NASDAQ: SAGE) and a co-founder of Voyager Therapeutics (NASDAQ: VYGR) where he served as President, Chief Executive Officer. Dr. Paul is the former director of the Appel Alzheimer’s Disease Research Institute at Weill Cornell Medical College and is currently a Professor of Psychiatry and Neurology at Washington University of St. Louis School of Medicine.\n\nDr. Paul has authored or co-authored more than 550 papers and book chapters. He is an elected fellow of the American Association for the Advancement of Science and a member of the National Academy of Medicine (NAM) of the National Academy of Sciences (NAS). He is also an elected Fellow Emeritus of the American College of Neuropsychopharmacology (ACNP) and served as ACNP President (1999). Dr. Paul is the Chairman of the Board of the Foundation for the NIH (FNIH) and previously served on the Science Board of the U.S. Food and Drug Administration (FDA), in addition to serving on many other advisory committees and receiving many awards and honors for his scientific research.\n\nDr. Paul received his bachelor’s degree in Biology and Psychology from Tulane University, and his M.S. and M.D. degrees from the Tulane University School of Medicine.\n\nDr. Gerberding joined the FNIH as CEO on May 16, 2022. She served before that as Chief Patient Officer and Executive Vice President, Population Health & Sustainability, at Merck & Co., Inc., where she was responsible for patient engagement, corporate social responsibility, Environmental/Social/Governance issues, and other functions. Formerly, Dr. Gerberding oversaw Global Public Policy and Strategic Communications for the company. She joined Merck in 2010 as President of Merck Vaccines and was instrumental in increasing access to the company’s vaccines to people around the world.\n\nPreviously, Dr. Gerberding was Director of the U.S. Centers for Disease Control and Prevention (CDC), where she led the agency through 40 emergency responses to public health crises, including the SARS-CoV-1 outbreak. She serves on the boards of the Mayo Clinic, National Health Council, Cerner Corporation, Case Western Reserve University, AfterNext HealthTech, and HilleVax. She also co-chairs the Center for Strategic and International Studies Commission on Strengthening America’s Health Security.\n\nDr. Gerberding received her undergraduate and M.D. degrees from Case Western Reserve University and a Master of Public Health at the University of California, Berkeley. She completed her internship and residency in Internal Medicine and fellowship in Clinical Pharmacology and Infectious Diseases at the University of California, San Francisco, where she is currently an Adjunct Associate Professor of Medicine.\n\nDr. Solomon H. Snyder is a distinguished service professor of Neuroscience, Pharmacology, and Psychiatry at the Johns Hopkins University School of Medicine. He is the founder of the Solomon H. Snyder Department of Neuroscience and served as its director from 1980 to 2006. He is world-renowned for his pioneering research in the identification of receptors for neurotransmitters and drugs and the elucidation of the actions of psychotropic agents.\n\nDr. Snyder completed his undergraduate work at Georgetown College and received his M.D. from the Georgetown Medical School. After further studies at the National Institutes of Health, he completed a residency in psychiatry at Johns Hopkins.\n\nAmong dozens of professional and academic honors, Dr. Snyder has received the U.S. National Academy of Science Award in Neuroscience, the Albany Prize in Medicine, the National Medal of Science, the Wolf Foundation Prize in Medicine, and the Albert Lasker Award for Basic Biomedical Research. He holds Honorary Doctor of Science degrees from Northwestern University, Georgetown University, Ben Gurion University, and the University of Maryland, among others.\n\nOver the course of his distinguished career, he has authored or co-authored more than 1,000 peer-reviewed publications and seven books. He currently serves as Associate Editor of the Proceedings of the National Academy of Sciences of the U.S., and is a member of the United States National Academy of Sciences and a Fellow of the American Philosophical Society and the American Academy of Arts and Sciences.\n\nDeeda Blair is a long-standing effective advocate for biomedical research. Mrs. Blair is Director Emeritus of the Albert and Mary Lasker Foundation and has worked closely with Mrs. Lasker on the Citizens Committee for the Conquest of Cancer. Together they initiated one of the most successful public health outreach campaigns ever launched: The National Campaign Against High Blood Pressure, which sought to educate the public concerning the need for blood pressure screening and involved a collaboration of federal Health Agencies, pharmaceutical companies, and the Advertising Council. Mrs. Blair has had a long-time interest in cancer research and served for more than 12 years on the Board of the American Cancer Society’s Research Committee, and in the 1970s, served on the Breast Cancer Task Force of the National Cancer Institute and served on the Board of Trustees of the Scripps Research Institute.\n\nSince 1982, Mrs. Blair has had a deep involvement in the Harvard School of Public Health, with a focus on Basic AIDS research. She is Co-Chairman of the Harvard AIDS Initiative International Advisory Council. She also serves as an Advisor to the Department of Immunology and Infectious Disease Through her time living in Asia and Europe as the wife of Ambassador William McCormick Blair, Jr., Mrs. Blair developed an abiding interest in the global approach to the prevention of infectious diseases and the development of vaccines. She worked as a longtime advisor to Sandoz/Novartis in developing academic collaborations and biotech alliances. She was a consultant to Health Care Ventures for a number of biotech companies.\n\nDr. Jay Bradner is the former President of the Novartis Institutes for Biomedical Research (NIBR), where he led thousands of scientists at six research sites around the world in the discovery of life-changing medicines for patients. Previously, Dr. Bradner was a clinician at the Dana-Farber Cancer Institute and an associate professor at Harvard Medical School. As an entrepreneur, he has co-founded five biotechnology startups. He has long been a proponent of open science, and when his lab at Dana-Farber discovered the bromodomain inhibitor JQ1, they took the unorthodox step of making it available to other researchers with no restrictions. Dr. Bradner brought this same “open science” approach when he joined Novartis in 2016. NIBR collaborates with an external network of academic and industry partners to facilitate cutting-edge science in areas of mutual interest. NIBR’s open science programs include the Global Scholars Program, which supports innovation through academic partnerships, and the annual Hackathon, which brings data scientists and NIBR researchers together to work on complex problems in the life sciences. He holds an M.D. from The University of Chicago Pritzker School of Medicine and an A.B. from Harvard University. Dr. Bradner will be a member of the Portfolio Oversight Committee of the FNIH Board.\n\nPrior to his retirement, Mr. Down was Vice Chairman of Mercer Management Consulting (now Oliver Wyman), responsible for the overall direction and management of the firm. Over the course of his career, he has been a senior advisor on strategic matters to a multitude of global organizations, including UPS, CSX/Sea-Land, AT&T, Agility, the U.S. Centers for Disease Control and Prevention (CDC), and Merck. He is a director of Colt DCS and recently retired as the Chairman of the Board of Shawmut Construction and Design. He is also a past director of CDM Smith, ProBuild, Transplace, Saint Boniface Haiti Foundation, Care Group, Horizon Lines, MTG, Oxfam, the CDC Foundation, Columbia University School of Engineering and Applied Science, and Outward Bound. He earned a BS in Engineering from Columbia University and an MBA from the Wharton School of the University of Pennsylvania.\n\nDr. Krall is Adjunct Professor of Neurology at the University of Rochester. He is a member of the Safety Board of Takeda Pharmaceuticals, is Chairman of the Board of Pierian Biosciences, and consults for a number of healthcare companies.\n\nFormer Chief Medical Officer for GlaxoSmithKline (Retired), Dr. Krall worked for four companies (Lorex Pharmaceuticals, Abbott Laboratories, Zeneca/AstraZeneca, and GlaxoSmithKline) over 25 years. His areas of expertise include the ethics of human subject experimentation, drug development, regulatory science, and the safety of medicines. Dr. Krall was a founding member of the Observational Medical Outcomes Partnership, served on its Executive Committee, and led its research subcommittee.\n\nDr. Krall is a graduate of Phillips Exeter Academy, holds a B.A. in Mathematics from Swarthmore College, an M.D. from the University of Pittsburgh, was a Staff Associate in the Epilepsy Branch of the National Institutes of Health, and completed his training in Neurology and a fellowship in Clinical Pharmacology at the University of Rochester.\n\nDr. Krall currently makes his home in Steamboat Springs, Colorado, where he serves as Chair of the Board of the Yampa Valley Community Foundation, is President of the Timbers Water and Sanitation District, and serves as advisor and ranch manager for BookTrails, a 501(c)3 literacy organization for children. Dr. Krall and his wife own and operate Off the Beaten Path, an independent bookstore, coffeehouse, and bakery café (www.steamboatbooks.com) – one of the 28 “coolest” independent bookstores in America (https://matadornetwork.com/read/28-coolest-independent-book-stores-us/).\n\nThroughout her career in medicine, Dr. Freda Lewis-Hall has been on the frontlines of health care as a clinician, educator, researcher, and leader in the biopharmaceuticals and life sciences industries. She served as Pfizer Inc.’s Chief Medical Officer and Executive Vice President until the end of 2018 and as Chief Patient Officer and Executive Vice President during 2019. In these roles, Dr. Lewis-Hall expanded outreach to patients, reshaped the focus on patient engagement and inclusion, improved health information and education, and amplified the voice of the patient within company culture and decision-making. She was responsible for the safe, effective, and appropriate use of Pfizer medicines and vaccines.\n\nBefore joining Pfizer, Dr. Lewis-Hall held senior leadership positions of Chief Medical Officer and Executive Vice President, Medicines Development at Vertex Pharmaceuticals; Senior Vice President, US Pharmaceuticals at Bristol Myers Squibb; Vice President, Research and Development, Product Development at Pharmacia Corporation; and Product Team Leader and Director at Eli Lilly and Company.\n\nDr. Lewis-Hall currently serves on the Board of Fellows of The Harvard Medical School, the Board of Advisors of the Dell Medical School, and the Board of Governors for the Patient-Centered Outcomes Research Institute. She currently serves on the corporate boards of Milliken and Company, a global diversified industrial manufacturer; 1Life Healthcare, Inc., a health services company; Exact Sciences, Inc., a molecular diagnostics company; and SpringWorks Therapeutics, a biopharmaceutical company.\n\nPrior to joining the biopharmaceutical industry, Dr. Lewis-Hall served as vice chairperson and associate professor in the Department of Psychiatry at Howard University College of Medicine and was an advisor to the National Institute of Mental Health. She earned a B.A. in Natural Sciences from The Johns Hopkins University and an M.D. from Howard University College of Medicine. She launched her medical career as a practicing physician and then focused her academic research on the effects of health care disparities and the impact of mental illness on families and communities.\n\nDr. Lewis-Hall is a Distinguished Fellow of the American Psychiatric Association and the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of the United Kingdom. She is a frequent speaker on issues such as improving patient safety and health outcomes, reducing stigma and health care disparities, women’s health, public health, corporate leadership, and diversity. Dr. Lewis-Hall is an accomplished developer of consumer education and medical outreach programs, including national television and radio shows such as segments on Dr. Phil, The Doctors, THE REAL, TEDMed, The Urban Health Report, and multiple online sites.\n\nDr. Edison Liu is Professor, President Emeritus, and Honorary Fellow of The Jackson Laboratory (JAX), an independent, not-for-profit organization focusing on mammalian genetics research, in order to advance human health. Between 2012 and 2021, he led JAX through a growth phase that doubled revenues and staff, quintupled the endowment, and expanded JAX’s footprint throughout the US and in Asia. Previously, Dr. Liu was the founding Executive Director of the Genome Institute of Singapore that established Singapore as a key player in functional genomics. At that time, he was also Chairman of the Health Sciences Authority, which is Singapore’s equivalent of the FDA, and the President of the Human Genome Organization (HUGO). Prior to moving to Singapore in 2001, Dr. Liu was the scientific director of the National Cancer Institute’s then Division of Clinical Sciences in Bethesda, Maryland. Dr. Liu’s research is focused on the functional genomics of human cancers, particularly breast cancer, uncovering new oncogenes and deciphering the dynamics of gene regulation on a genomic scale. He has authored over 320 scientific papers and reviews and co-authored two books. In his spare time, he pursues jazz piano and composition and writes for the lay public on science, medicine, and society.\n\nDr. Gilbert Omenn is the Harold T. Shapiro Distinguished University Professor of Computational Medicine & Bioinformatics, Internal Medicine, Human Genetics and Public Health, and Founding Director of the Center for Computational Medicine & Bioinformatics at the University of Michigan, Ann Arbor. His research is focused on proteo-genomics and bioinformatics of cancers. He led the global Human Proteome Project (www.hupo.org) for the past decade. He previously worked on biochemical genetics of the brain, cancer prevention, health promotion and disease prevention for older adults, and science and health policy. He is an author of 657 publications with 43,621 citations/h-index 87 and editor/author of 18 books.\n\nHe was a Research Associate with Christian B. Anfinsen at the National Institute of Arthritis and Metabolic Diseases (NIAMD); a Howard Hughes Medical Institute Investigator at the University of Washington (UW); and a member of the National Cancer Advisory Board; the National Heart, Lung and Blood Institute Council, the Society of Fellows of the National Center for Minority Health & Health Disparities, and the Scientific Management Review Committee for the National Institutes of Health. He was Dean of the School of Public Health & Community Medicine at the UW and Executive Vice-President for Medical Affairs and CEO of the Health System at the University of Michigan. He served as a White House Fellow at the U.S. Atomic Energy Commission, Associate Director of the White House Office of Science & Technology Policy and the Office of Management & Budget, and President of the American Association for the Advancement of Science. In the 1990s, he chaired the Presidential/Congressional Commission on Risk Assessment & Risk Management. He served on the boards of Amgen, Inc. and Rohm & Haas Company. He currently serves on boards of the Foundation for the National Institutes of Health, Hastings Center for Bioethics, the Center for Public Integrity, the Weizmann Institute of Science, and biotech firms.\n\nDr. Omenn is an elected member of the National Academy of Medicine, the Association of American Physicians and the American Academy of Arts and Sciences, and is a fellow of the American College of Physicians, the National Academy for Social Insurance, and the AAAS. He received the Walsh McDermott Medal from the National Academy of Medicine and the David E. Rogers Award from the Association of American Medical Colleges. He holds a B.A. from Princeton, an M.D. from Harvard, and a Ph.D. in Genetics from the University of Washington. He has three children and eight grandchildren. He is a musician and tennis player.\n\nCharles A. Reinhart III is the Chief Financial Officer at Pacira. He is responsible for overseeing all financial and capital market activities at Pacira, including accounting, financial reporting, financial planning and analysis, and investor relations.\n\nPrior to joining Pacira, Mr. Reinhart served as Chief Financial Officer of Covis Pharmaceuticals, Inc. From September 2011 to August 2014, he served as Executive Vice President and Chief Financial Officer of Archimedes Pharma Ltd. Mr. Reinhart also served as Senior Vice President and Chief Financial Officer of PharmAthene, Inc., a biodefense company engaged in the development of next generation medical countermeasures against biological and chemical threats, from 2009 to 2011. He has also held senior financial roles at Millennium Pharmaceuticals, Inc., Cephalon, Inc. and several early-stage life sciences companies. He also served as a director of Osiris Therapeutics, Inc. (Nasdaq: OSIR) from September 2018 until it was acquired in April 2019. Mr. Reinhart has successfully built and managed finance organizations within rapidly growing companies, responsible for accounting and financial reporting, financial planning and analysis, tax, treasury, risk management and procurement. He has worked closely with commercial teams to evaluate sales operations, monitor product pricing and implement contracting strategies. In addition, he has significant experience in investor relations, corporate development and capital raising. He has been integrally involved in equity and debt financing transactions, as well as the evaluation, acquisition and integration of multiple products and companies.\n\nMr. Reinhart earned his Bachelor of Science degree from Lehigh University and his MBA from the Wharton School of the University of Pennsylvania. He is also a CPA.\n\nDr. Charles A. Sanders is the former Chairman and CEO of Glaxo Inc., and a former member of the Board of Glaxo PLC. Before joining Glaxo, Dr. Sanders spent eight years with Squibb Corp., where he held several posts, including Vice Chairman, Chief Executive Officer of the Science and Technology Group, and Chairman of the Science and Technology Committee of the Board.\n\nPreviously, Dr. Sanders was General Director of Massachusetts General Hospital in Boston and Professor of Medicine at Harvard Medical School. Dr. Sanders is a member of the Institute of Medicine of the National Academy of Sciences, a member of the Board of Trustees of the Center for Strategic and International Studies, Chairman Emeritus and Board Member of Project HOPE, and a member of multiple corporate boards. He is past chairman of the New York Academy of Sciences (NYAS), the Commonwealth Fund, and the Overseers Committee to Visit the Harvard Medical School. A native of Dallas, Dr. Sanders is a graduate of Southwestern Medical College of the University of Texas. Dr. Sanders and his wife, Ann, live in Durham, North Carolina.\n\nDr. Ellen V. Sigal, Ph.D., is the founder and Chairperson of Friends of Cancer Research, a Washington, D.C.-based not-for-profit organization dedicated to accelerating the nation’s progress toward cancer prevention and treatment. The organization mobilizes public support for cancer research funding and providing education on key public policy issues. Dr. Sigal also holds leadership positions within a broad range of cancer advocacy and public policy organizations, including Duke University’s Comprehensive Cancer Center, the Johns Hopkins Cancer Center Advisory Council, the Foundation for the National Institutes of Health, the American Association for Cancer Research (AACR), and the American Cancer Society. Dr. Sigal serves on the Board of Scientific Advisors for the National Cancer Institute and, most recently, was named to the National Institute of Health Director’s Council of Public Representatives.\n\nIn her more than twenty years of commitment to advancing the war on cancer, Dr. Sigal has served in numerous critical public positions. Dr. Sigal was a Presidential Appointee to the National Cancer Advisory Board from 1992-1998, where she chaired the Budget and Planning Committee, which oversees the federal cancer budget. Additionally, Dr. Sigal also serves on the National Dialogue on Cancer’s research advisory panel and previously held leadership positions with the Foundation for the American Society of Clinical Oncology.\n\nIn 1998, Dr. Sigal was named Vice Chairman of the Board of The March – a national grassroots advocacy group that brought thousands of volunteers to Washington to liaise with Congress and set a new advocacy agenda for cancer research and treatment. Dr. Sigal has also been instrumental in harnessing the energies of Hollywood on behalf of cancer research—serving as President of The Creative Community Task Force for Cancer Research.\n\nPrior to her work in cancer research advocacy, Dr. Sigal enjoyed a highly successful and influential business career in commercial real estate. Her firm, Sigal Development, financed and developed major projects throughout the Washington and mid-Atlantic region—a portfolio in excess of one billion dollars. For her efforts on behalf of cancer research advocacy, Dr. Sigal received the 1998 American Association for Cancer Research National Leadership Award, the 1999 Sidney Kimmel Cancer Center National Leadership Award, and the 2002 American Society of Clinical Oncology Special Recognition Award.\n\nDr. Sigal received her Ph.D. from Rutgers University in Russian History.\n\nJim Weiss is the Chairman and Founder of Real Chemistry, which provides data-driven, tech-enabled, integrated marketing communications and commercial and medical solutions for the life science sector. Over the past 20 years, he built Real Chemistry from a one-person consultancy to a global health innovation company that uses real-world data, proprietary technologies, and analytical insights to solve the healthcare industry’s most significant challenges. He started his corporate career at Genentech and is now an investor, mentor, and strategic advisor to those looking to innovate at the intersection of technology and life sciences. Mr. Weiss has been named Agency Entrepreneur of the Year (2021), a Top 50 Health Influencer (2016, 2017, 2018, 2019, 2020), Innovator of the Year (2020), and was inducted into the Syracuse University’s S.I. Newhouse School of Public Communications’ 50 Forward as one of its most accomplished graduates. Mr. Weiss is co-chair of the Advancement and Communications Committee of the FNIH Board and a member of the Executive Committee.\n\nDr. Elias Zerhouni was most recently the President, Global Research & Development, and a member of the Executive Committee for Sanofi from January 2011 to July 2018.\n\nDr. Zerhouni’s academic career was spent at the Johns Hopkins University and Hospital where he was professor of Radiology and Biomedical Engineering and senior adviser for Johns Hopkins Medicine. He served as Chair of the Russell H. Morgan Department of Radiology and Radiological Sciences, Vice Dean for Research, and Executive Vice Dean of the School of Medicine from 1996 to 2002, before his appointment as Director of the National Institutes of Health from 2002 to 2008.\n\nIn 2009, President Obama appointed Dr. Zerhouni as one of the first presidential U.S. science envoys.\n\nDr. Zerhouni also served as senior fellow to the Bill and Melinda Gates foundation from 2009 to 2010. He authored more than 200 scientific publications and is a member of the U.S. National Academy of Medicine and the U.S. National Academy of Engineering."
    }
}